Branched-chain amino acid deficiency stabilizes insulin-induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells

Journal of Cellular Biochemistry

Volumn 113, Issue 10, 2012, Pages 3113-3121

  Miuma, Satoshi ^a   Ichikawa, Tatsuki ^a   Arima, Kazuhiko ^a   Takeshita, Shigeyuki ^a   Muraoka, Toru ^a   Matsuzaki, Toshihisa ^a   Ootani, Masashi ^a   Shibata, Hidetaka ^a   Akiyama, Motohisa ^a   Ozawa, Eisuke ^a   Miyaaki, Hisamitsu ^a   Taura, Naota ^a   Takeshima, Fuminao ^a   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

BCAA; decay; HCC; hyperinsulinemia; stability; vegf

Indexed keywords

BRANCHED CHAIN AMINO ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; ISOLEUCINE; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; VALINE; VASCULOTROPIN;

AMINO ACID DEFICIENCY; ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; RNA DEGRADATION; SIGNAL TRANSDUCTION;

AMINO ACIDS, BRANCHED-CHAIN; CARCINOMA, HEPATOCELLULAR; CULTURE MEDIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN; LIVER NEOPLASMS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; TIME FACTORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865020690     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24188     Document Type: Article

References (40)

1. Ahmed SI, Thomas AL, Steward WP,. 2004. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 16 (Suppl 4): 59-63.
2. Biswas S, Gupta MK, Chattopadhyay D, Mukhopadhyay CK,. 2007. Insulin-induced activation of hypoxia-inducible factor-1 requires generation of reactive oxygen species by NADPH oxidase. Am J Physiol Heart Circ Physiol 292: H758-H766.
3. Bosch FX, Ribes J, Diaz M, Cleries R,. 2004. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127: S5-S16.
4. El-Serag HB, Mason AC,. 2000. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160: 3227-3230.
5. Folkman J, Watson K, Ingber D, Hanahan D,. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
6. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL,. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211.
7. Hirota K, Semenza GL,. 2005. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338: 610-616.
8. Ijichi C, Matsumura T, Tsuji T, Eto Y,. 2003. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. Biochem Biophys Res Commun 303: 59-64.
9. Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH, Wang HY,. 2004. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J Gastroenterol 10: 676-681.
10. Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH, Wang HY,. 2004. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study. World J Gastroenterol 10: 643-648.
11. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK,. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369.
12. Kano T, Nagaki M, Takahashi T, Ohnishi H, Saitoh K, Kimura K, Muto Y,. 1991. Plasma free amino acid pattern in chronic hepatitis as a sensitive and prognostic index. Gastroenterol Jpn 26: 344-349.
13. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA,. 2009. Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature. Cancer 115: 4895-4906.
14. Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Banda MJ,. 1983. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 221: 1283-1285.
15. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S,. 2007. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 102: 1939-1946.
16. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL,. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
17. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N,. 1999. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107: 450-455.
18. Miuma S, Ichikawa T, Taura N, Shibata H, Takeshita S, Akiyama M, Motoyoshi Y, Ozawa E, Fujimoto M, Kawashimo H, Miyaaki H, Eguchi K, Nakao K,. 2009. The level of fasting serum insulin, but not adiponectin, is associated with the prognosis of early stage hepatocellular carcinoma. Oncol Rep 22: 1415-1424.
19. Murata K, Moriyama M,. 2007. Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis. Cancer Res 67: 3263-3268.
20. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H,. 2005. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3: 705-713.
21. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Ohashi Y,. 2006. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35: 204-214.
22. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ,. 1994. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5: 89-97.
23. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK,. 2001. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116: 838-845.
24. Park JE, Keller GA, Ferrara N,. 1993. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326.
25. Park YN, Kim YB, Yang KM, Park C,. 2000. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124: 1061-1065.
26. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J,. 2001. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study. Ann Surg 233: 227-235.
27. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ,. 2009. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis. Br J Cancer 100: 1385-1392.
28. Semenza GL,. 2002. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8: S62-S67.
29. Sharp FR, Bernaudin M,. 2004. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 5: 437-448.
30. Shweiki D, Itin A, Soffer D, Keshet E,. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
31. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T,. 2002. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512: 157-162.
32. Takahashi H, Shibuya M,. 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109: 227-241.
33. Taura N, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T, Fukuta M, Kawashimo H, Fujimoto M, Kusumoto K, Motoyoshi Y, Shibata H, Abiru N, Yamasaki H, Eguchi K,. 2006. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 101: 2752-2759.
34. Underiner TL, Ruggeri B, Gingrich DE,. 2004. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 11: 731-745.
35. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S,. 2001. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48: 87-96.
36. Wang GL, Jiang BH, Rue EA, Semenza GL,. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514.
37. Weidner N, Semple JP, Welch WR, Folkman J,. 1991. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
38. Yoo PS, Mulkeen AL, Cha CH,. 2006. Post-transcriptional regulation of vascular endothelial growth factor: Implications for tumor angiogenesis. World J Gastroenterol 12: 4937-4942.
39. Yoshiji H, Noguchi R, Kaji K, Ikenaka Y, Shirai Y, Namisaki T, Kitade M, Tsujimoto T, Kawaratani H, Fukui H,. 2010. Attenuation of insulin-resistance- based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol 45: 443-450.
40. Yu MC, Yuan JM,. 2004. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127: S72-S78.